News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GE Healthcare Launches Xuri™ IL-2 Growth Factor For The Reliable Activation And Expansion Of T-Lymphocytes



5/14/2014 9:51:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

May 14, 2014 -- Xuri™ IL-2 is a dedicated cell therapy ancillary product for the ex vivo cultivation of T-lymphocytes. Xuri IL-2’s defined level of biological activity removes the need for revalidation of each lot and strongly improves reproducibility, thereby minimizing process development time and improving scale out capacity.

Xuri IL-2 features low endotoxin levels (<0.025 EU/µg), is produced under a GMP license certified and regularly audited, quality controlled under ISO9001:2008 and in accordance with the International Conference on Harmonization (ICH) guideline. Xuri IL-2 is supplied with comprehensive instructions for straightforward expansion in static culture and with the Xuri Cell Expansion Systems W5 and W25.

Also now available is IL-2 for preclinical use, a cost efficient alternative for the cultivation of T-lymphocytes in proof-of-principle and basic research experiments. The close equivalence between IL-2 and Xuri IL-2 simplifies the transition from research to process development for cell therapy manufacturing with minimized optimization time while supporting regulatory compliance.

Xuri products are supplied with a comprehensive documentation support package that follows USP <1043> requirements applicable to a supplier of ancillary material for cell, gene and tissue-engineered products to enable a full assessment and documentation of the production processes. This contributes significantly to facilitating risk assessment and validation in cell therapy manufacturing.

For further information please visit:

https://promo.gelifesciences.com/GL/XURI/expansion.html

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES